Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is OLMESARTAN MEDOXOMIL USP, with a corresponding US DMF Number 20417.
Remarkably, this DMF maintains an Active status since its submission on March 23, 2007, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 04, 2013, and payment made on August 27, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II